ATE222122T1 - Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen - Google Patents

Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen

Info

Publication number
ATE222122T1
ATE222122T1 AT97916665T AT97916665T ATE222122T1 AT E222122 T1 ATE222122 T1 AT E222122T1 AT 97916665 T AT97916665 T AT 97916665T AT 97916665 T AT97916665 T AT 97916665T AT E222122 T1 ATE222122 T1 AT E222122T1
Authority
AT
Austria
Prior art keywords
immunotoxins
target cells
cell populations
cells
harvested cell
Prior art date
Application number
AT97916665T
Other languages
English (en)
Inventor
Oystein Fodstad
Gunnar Kvalheim
Siri Juell
Meng Yu Wang
Olav Engebraten
Original Assignee
Oystein Fodstad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oystein Fodstad filed Critical Oystein Fodstad
Application granted granted Critical
Publication of ATE222122T1 publication Critical patent/ATE222122T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081Purging biological preparations of unwanted cells
    • C12N5/0093Purging against cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Electrotherapy Devices (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97916665T 1996-03-13 1997-03-12 Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen ATE222122T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO961031A NO961031D0 (no) 1996-03-13 1996-03-13 Fremgangsmåte til å drepe uönskede målceller
PCT/NO1997/000074 WO1997033611A1 (en) 1996-03-13 1997-03-12 Method of killing target cells in harvested cell populations with one or more immunotoxins

Publications (1)

Publication Number Publication Date
ATE222122T1 true ATE222122T1 (de) 2002-08-15

Family

ID=19899150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97916665T ATE222122T1 (de) 1996-03-13 1997-03-12 Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen

Country Status (18)

Country Link
US (1) US7198787B2 (de)
EP (1) EP0954329B1 (de)
JP (1) JP2000507230A (de)
CN (1) CN1218411A (de)
AT (1) ATE222122T1 (de)
AU (1) AU710184B2 (de)
BR (1) BR9708049A (de)
CA (1) CA2248620A1 (de)
DE (1) DE69714775T2 (de)
HU (1) HUP9901597A3 (de)
IL (1) IL126014A0 (de)
NO (1) NO961031D0 (de)
NZ (1) NZ331763A (de)
PL (1) PL328804A1 (de)
RU (1) RU2182493C2 (de)
SK (1) SK125798A3 (de)
TR (1) TR199801795T2 (de)
WO (1) WO1997033611A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
RU2198681C2 (ru) * 2000-12-27 2003-02-20 Московский научно-исследовательский онкологический институт им. П.А. Герцена Моноклональное антитело ико25, специфичное к антигену мис1, противоопухолевое средство
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
RU2283119C1 (ru) * 2005-03-29 2006-09-10 Андрей Степанович БРЮХОВЕЦКИЙ Препарат аутологичных гемопоэтических стволовых клеток, способ его получения, криоконсервации и использования для лечения травматической болезни центральной нервной системы
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US7496291B2 (en) * 2006-03-21 2009-02-24 Hewlett-Packard Development Company, L.P. Method and apparatus for interleaved image captures
EP2589668A1 (de) 2006-06-14 2013-05-08 Verinata Health, Inc Analyse seltener Zellen mittels Probentrennung und DNA-Etiketten
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
ES2620012T3 (es) 2008-09-20 2017-06-27 The Board Of Trustees Of The Leland Stanford Junior University Diagnóstico no invasivo de la aneuploidia fetal por secuenciación
US8524669B2 (en) * 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
MX2011012625A (es) 2009-05-27 2012-04-20 Dana Faber Cancer Inst Inc Inhibicion de la inflamacion usando los antagonistas de mucina 1 (muc1).
CN102127148B (zh) * 2010-01-14 2013-04-03 中国农业科学院北京畜牧兽医研究所 血管内皮细胞表面决定簇部分多肽及其应用
MX2013012905A (es) * 2011-05-06 2014-04-25 Us Gov Health & Human Serv Inmunotoxina recombinante dirigida a la mesotelina.
CN107748256B (zh) * 2017-10-11 2020-04-14 厦门骁科码生物科技有限公司 一种循环肿瘤细胞的液体活检检测方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219411A (en) 1978-09-18 1980-08-26 California Institute Of Technology Cell sorting apparatus
US4230685A (en) 1979-02-28 1980-10-28 Northwestern University Method of magnetic separation of cells and the like, and microspheres for use therein
US4510244A (en) 1980-04-17 1985-04-09 The Board Of Trustees Of The Leland Stanford Jr. University Cell labeling with antigen-coupled microspheres
AU563827B2 (en) 1982-07-01 1987-07-23 Millipore Corp. Filtration apparatus
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4704255A (en) 1983-07-15 1987-11-03 Pandex Laboratories, Inc. Assay cartridge
US4920061A (en) 1984-03-02 1990-04-24 The University Of Texas System Biological magnetic colloids
US4752569A (en) 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US5019497A (en) 1984-11-09 1991-05-28 Lennart Olsson Human squamous lung carcinoma cell specific antigens and antibodies
US4710472A (en) 1985-09-25 1987-12-01 The United States Of America As Represented By The Secretary Of The Navy Magnetic separation device
US5076950A (en) 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
EP0241042A3 (de) 1986-04-11 1988-05-04 Hitachi, Ltd. Verfahren zur Zelle-Analyse
US4895706A (en) 1986-10-28 1990-01-23 Costar Corporation Multi-well filter strip and composite assemblies
US4857452A (en) 1986-12-04 1989-08-15 E. I. Du Pont De Nemours And Company Assay for carcinoma of breast, colon and ovary
ZA881715B (en) * 1987-03-11 1988-09-06 Farmitalia Carlo Erba S.R.L. Immunoglobulin conjugates
US5194300A (en) 1987-07-15 1993-03-16 Cheung Sau W Methods of making fluorescent microspheres
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5256532A (en) 1988-05-02 1993-10-26 Zynaxis Technologies, Inc. Methods, reagents and test kits for determination of subpopulations of biological entities
FR2638848B1 (fr) 1988-11-04 1993-01-22 Chemunex Sa Procede de detection et/ou de dosage dans un milieu liquide ou semi-liquide d'au moins une substance organique, biologique ou medicamenteuse soluble, par une methode d'agglutination
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5185254A (en) * 1988-12-29 1993-02-09 The Wistar Institute Gene family of tumor-associated antigens
GB8905001D0 (en) 1989-03-04 1989-04-19 Univ Leicester Screening for natural products of microbial metabolism
WO1990010692A1 (en) 1989-03-15 1990-09-20 University Of Florida Monoclonal antibody for use in detection and treatment of childhood leukemia
US5081030A (en) 1989-04-25 1992-01-14 The Johns Hopkins University Release of cells from affinity matrices
DE3919873A1 (de) 1989-06-19 1990-12-20 Behringwerke Ag Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
DE3919923A1 (de) 1989-06-19 1990-12-20 Behringwerke Ag Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung
GB8916859D0 (en) 1989-07-24 1989-09-06 Dynal As Hapten linking
SU1698287A1 (ru) * 1989-10-31 1991-12-15 Всесоюзный онкологический научный центр АМН СССР Штамм гибридных культивируемых клеток животных MUS мUSсULUS L. - продуцент моноклонального антитела к антигену мембран жировых глобул женского молока
JPH05503632A (ja) * 1989-12-14 1993-06-17 スローン ― ケターリング・インスティチュート・フォー・キャンサー・リサーチ モノクローナル抗体m195の超可変領域の治療的使用およびその構築
GB8929297D0 (en) 1989-12-29 1990-02-28 Dynal As Method of separation
GB9007966D0 (en) 1990-04-09 1990-06-06 Dynal As Antigen/anti-antigen cleavage
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5340719A (en) 1990-11-23 1994-08-23 Corporation Coulter Method and apparatus for optically screening microscopic cells
JPH05107249A (ja) 1991-02-04 1993-04-27 Toyobo Co Ltd リガンド・レセプター反応の高感度検出法
US5491068A (en) 1991-02-14 1996-02-13 Vicam, L.P. Assay method for detecting the presence of bacteria
AU2115092A (en) 1991-10-08 1993-04-22 Eastman Kodak Company Method, test device and kit for assay of specific binding ligand using controlled flow through filtration membrane
US5290707A (en) 1991-11-25 1994-03-01 The United States Of America As Represented By The Secretary Of The Army Method for detection of microorganisms
US5256542A (en) 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
DE69301725T2 (de) 1992-03-20 1996-07-25 Celsis Int Plc Verfahren und gerät zur analyse von biologischem material
US5422277A (en) 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
WO1994002016A1 (en) * 1992-07-28 1994-02-03 Steven Kessler Methods for positive immunoselection of stem cells
ES2216034T3 (es) 1992-09-14 2004-10-16 Sri International Indicadores de conversion creciente destinados a ensayos biologicos y otros utilizando tecnicas de excitacion por laser.
WO1994007138A1 (en) 1992-09-14 1994-03-31 Fodstad Oystein Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
FR2700010B1 (fr) 1992-12-24 1995-03-17 Rocher Yves Biolog Vegetale Méthode et dispositif pour tester la réactivité de cellules à l'égard de produits.
US5374531A (en) 1993-03-22 1994-12-20 Zynaxis, Inc. Immunoassay for determination of cells
US5514340A (en) 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
AUPN214095A0 (en) 1995-04-03 1995-04-27 Australian Water Technologies Pty Ltd Method for detecting microorganisms using flow cytometry

Also Published As

Publication number Publication date
EP0954329B1 (de) 2002-08-14
DE69714775D1 (de) 2002-09-19
CN1218411A (zh) 1999-06-02
NO961031D0 (no) 1996-03-13
JP2000507230A (ja) 2000-06-13
HUP9901597A3 (en) 2000-06-28
EP0954329A1 (de) 1999-11-10
IL126014A0 (en) 1999-05-09
HUP9901597A2 (hu) 1999-08-30
NZ331763A (en) 2000-01-28
US20020151689A1 (en) 2002-10-17
PL328804A1 (en) 1999-02-15
AU710184B2 (en) 1999-09-16
AU2522997A (en) 1997-10-01
CA2248620A1 (en) 1997-09-18
RU2182493C2 (ru) 2002-05-20
DE69714775T2 (de) 2003-04-24
TR199801795T2 (xx) 1998-12-21
US7198787B2 (en) 2007-04-03
SK125798A3 (en) 1999-05-07
BR9708049A (pt) 1999-07-27
WO1997033611A1 (en) 1997-09-18

Similar Documents

Publication Publication Date Title
DE69714775D1 (de) Verfahren zur Tötung von Zielzellen in geernteten Zellpopulationen mit Hilfe von zwei Immunotoxinen
DE60235464D1 (de) Knochenmarkersatzmaterial-verbundwerkstoff, verfahren zu seiner herstelllung und kit
DK0953046T3 (da) Human hæmatopoietisk stam- og progenitorcelleantigen og fremgangsmåder til anvendelse af dette
ATE266723T1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
MXPA02006145A (es) Metodo para el aislamiento de arn de especimenes de tejido incluido en parafina fijo en formalina.
EP1083828A4 (de) Biotechnisch erzeugte gefässprothese für die implantation
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
AU9058091A (en) Preparation of nucleic acid samples
DE60043229D1 (de) Zusammensetzung zur gefässbeschichtung
ATE257392T1 (de) Verfahren zur modulierung der neovaskularisierung und/oder des wachstums von kollateraler arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
DE69927507D1 (de) Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung
EP1102988B8 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
ATE428928T1 (de) Verfahren zur einführung von heterologischen zellen in fische
PT941329E (pt) Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
EP1304123A3 (de) Verfahren zur Modulierung des Wachstums kollateraler Arterien und / oder anderer Arterien aus bestehenden arteriolen Verbindungen
CA2517140A1 (en) Use of pc-cell derived growth factor (pcdgf) for increasing the proliferation of b cells
DE60038630D1 (de) Verfahren zur ex vivo bildung von säugetier-knochen und dessen verwendungen
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
DE69837212D1 (de) Verfahren zur induzierung der osteoblastischen differenzierung der zellen des menschlichen extramedullären fettgewebes
EP1728857A3 (de) Bereitstellung von Lebergewebe.
NO984175L (no) FremgangsmÕte til Õ drepe mÕlceller i h°stede cellepopulasjoner med en eller flere immunotoksiner
WO2000036420A3 (en) Differential expression in primary breast cancer
EP1826560A3 (de) Verfahren zur Einführung von heterologischen Zellen in Fische
MX9710291A (es) Inhibidores ligantes de proteinas de fijacion con factor de crecimiento del tipo de insulina y metodos de uso para los mismos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties